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ABSTRACT 
BACKGROUND Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which results in 
inflammation and eventual damage in a broad range of organ systems. Trombocytopenia is a common complication 
in patients with SLE, but amegakaryocyte trombocytopenia (AMT) is a rare disorder in SLE that characterized by 
isolated thrombocytopenia as a consequence of a marked decrease in or total absence of megakaryocytes in an 
otherwise normal bone marrow. 
CASE Lu, a wellnourished 13 y.o girl, complaining for high fever for 2 weeks, diminished body weight, artralgia, 
furunculosis, oral apthae and palour for 1 year, and bruising extremities for 2 motnhs. There was hepatosplenomegali. 
Laboratory findings: Hb 8.8 gr/dL, hct 27%, leucocytes 1.000/µL (ANC 230/µL), trombocytes 25,000/µL. Bone 
marrow puncture revealed amegacaryocyte thrombocytopenia, absence of megacaryocyte while erythropoesis and 
granulopoesis were normal. Anti ds DNA 223.8 iu/ml (+); ANA test 101.7 unit (+), microalbumin urine 10 mcg/mg 
(-), C3 complement 40 mg/dL (), ACA IgM 20.6 U/ml (+), ACA IgG 17.3 U/mL (+). The case fulfilled 5 criteria of 
ACR for SLE. The patient administered ceftazidim and gentamycin for febrile neutropenia, and high dose 
methylprednisolon injection for SLE.  
CONCLUSION A rare case of amegakaryocyte thrombocytopenia in juvenila SLE has been successfully diagnosed. 
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Systemic lupus erythematosus (SLE) is a 
severe, chronic autoimmune disease which 
results in inflammation and eventual damage in a 
broad range of organ systems. SLE is a relatively 
rare disease in childhood with an estimated 
incidence ranging from 10-20/ 100,000 children, 
depending on ethnicity. Childhood SLE affects 
girls more often than boys, and it can occur at any 
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age, SLE becomes more frequent after five years 
of age and is increasingly prevalent after the first 
decade of life. 1-3 
Trombocytopenia is a common complication 
in patients with SLE, and its prevalence ranges 
from 7–30%. The two main mechanisms of 
thrombocytopenia in SLE are increased platelet 
destruction mediated by antiplatelet 
autoantibodies, similar to the mechanism seen in 
immune thrombocytopenic purpura (ITP), and 
impaired thrombopoiesis, due to the absence of or 
a decreased number of megakaryocytes in the 
bone marrow. The latter disorder is also known as 
amegakaryocytic thrombocytopenia (AMT). 
AMT is a rare disorder characterized by isolated  
thrombocytopenia that is often severe (platelet 
count <20–30×109 /L), as a consequence of a 
marked decrease in or total absence of 
megakaryocytes in an otherwise normal bone 
marrow.4,5  
We report a rare case of AMT in 13 year-old 
girl with SLE that mimicked malignancy. The 
aim of presenting this case is to increase 
awareness of this condition since it is not 
generally considered as SLE. 
CASE REPORT 
Lu, a 13 year-old wellnourished girl was 
referred for suspected Acute Leukemia. She had 
suffered from a high fever since 14 days before 
admission and often got relapsing fever for 1 
year. There were history of palour, weakness, 
recurrent oral apthae and furunculosis, and 
arthralgia for 1 year. There was also recurrent 
bruising extremities for 2 months. From referreal 
hospital there was history of pancytopenia and 
febrile neutropenia. The patient had administered 
with Ceftazidim and PRC transfusion. In addition 
there was no history of malignancy, blood 
diseases, or other chronic diseases such as 
tuberculosis or hepatitis in her familiy. She got 
menarche 1 month before admission. 
She looked alert, moderately ill, with fever 
(axillary temperature 380C). There was oral 
ophthae, enlargement of the liver 1/3-1/3 sharp 
edge, enlargement of the spleen Schuffner 1, 
bruising and furuncle on the thigh. The other 
physical examination were normal.  
Initial laboratory findings showed hemoglobin 
8.8 gr/dL, Hematocrites 27%, leucocytes 
1.000/µL (ANC 230/µL), trombocytes 
25,000/µL, normal renal function test (ureum 
19.7 mg/dl, creatinine 0.3 mg/dl), normal liver 
function test (AST 20 U/L, ALT 25 U/L), CRP 
1.53 mg/dl. Urineanalysis, and coagulation 
function  were normal. The anteroposterior chest 
X-ray was normal, and the abdominal ultrasound 
was revealed hepatosplenomegali. ECG was 
normal.  
Based on the history taking, physical 
examination and laboratory findings, the patient 
was suspected for malignancy. She then 
underwent Bone Marrow Aspirations (BMA) that 
revealed normocellularity with good erytropoesis 
and granulopoesis activities, and diminished 
megakaryocyte activity (figure1). Fe storage was 
positive and her  Coomb’s test was negative.  
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Figure1. Bone Marrow Aspiration revealed 
amegakaryocyte thrombocytopenia (AMT) 
Based on recent supportive examinations, 
pancytopenia due to amegakaryocytic 
thrombocytopenia due to Systemic Lupus 
Erythematosus with differential diagnosis 
infection were diagnosed. 
The laboratory finding performed later 
indicated a sterile urine culture,  HbsAg (-); anti 
HCV (-); IgM Salmonella (-); Anti dsDNA 223.8 
iu/ml (positive > 92.6 IU/mL); ANA test 101.7 
unit (+). The next supportive examination 
revealed microalbumin urine 10 mcg/ mg (), C3 
complement 40 mg/dL (), ACA IgM 20.6 U/ml 
(+), ACA IgG 17.3 U/mL (+). The findings 
fulfilled 5 criteria of ACR for SLE. 
 The patient was given intravenous methyl 
prednisolon 1x80 mg (2mgs/kgBW/day), 
antibiotics  were continued until ANC > 500 /µl 
with ceftazidim and gentamycin due to prolonged 
febrile neutopenia. She administered sunblock 
cream, nutritional diet as many as RDA (2500 
kkal), and vitamin D s to prevent osteoporosis.   
 On the 11th day of admission she got better, no 
fever, improvement of oral apthae and furuncle. 
The complete blood count revealed Hb 11.4 
md/dL, leucocyte 2900 mm3, PCV , trombocytes 
26,000 /mm3, ANC 870. The administration of 





SLE in children affects girls more often than 
boys, and becomes more frequent after five years 
of age and is increasingly prevalent after the first 
decade of life. In this case, SLE was diagnosed in 
a 13 year-old girl  who had just entered puberty.1-
3 
The patient was refered from a private hospital 
for suspected acute leukemia. Constitutional 
symptoms such as fatigue, fever and weight loss, 
with organomegali (hepatosplenomegali) and 
pancytopenia are very common in malignancy. 1-
3,6,7 Presentation of pancytopenia is alarming and 
indicates the possibility of either a bone marrow 
failure syndrome or acute malignancy 
particularly when associated with 
lymphadenopathy or organomegaly. Aplastic 
anemia and ALL are the most common and the 
most dangerous established causes of 
pancytopenia. Acute  leukemia itself may mimic 
initially as aplastic anemia. 7 
The patient underwent a Bone Marrow 
Aspiration (BMA) procedure that revealed 
amegakaryocyte thrombocytopenia (AMT. It can 
occur alone as an idiopathic entity; in association 
with lymphoproliferative disorders, SLE, and 
other autoimmune diseases, infections, solid 
tumors, B12 deficiency, and ethanol abuse or 
after exposure to drugs. AMT can also be the 
initial manifestation of bone marrow disorders 
such as myelodysplastic syndromes or aplastic 
anemia. Due in part to its rarity and in part to its 
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heterogeneous nature, the pathogenetic 
mechanisms of this disorder have not been well 
defined; in fact, its etiology is likely to be diverse. 
4,5,8 
 The laboratory finding performed later 
showed a sterile urine culture,  Anti dsDNA 223,8 
iu/ml (+); ANA test 101,7 unit (+), C3 
complement 40 mg/dL (), ACA IgM 20.6 U/ml 
(+), ACA IgG 17.3 U/mL (+). Based on these 
findings, the patient fulfilled 5 criteria for ACR 
for SLE, thus the AMT was due to SLE. (Table 
1)9 
 SLE is a multisystem disorder with wide-
ranging clinical and laboratory manifestations. Of 
these, thrombocytopenia is a common finding 
with platelet counts less than 100 x 109/L with a 
prevalence that ranges from 8-30% of the 
patients. The purported mechanism leading to 
thrombocytopenia in SLE includes anti-
GPIIb/IIIa antibody-mediated platelet destruction 
and inhibition of megakaryopoesis by antibodies 
directed against the TPOR (cMpl). Subsequent 
studies have suggested that AMT can develop as 
a consequence of cell-mediated inhibition or 
destruction of megakaryocytes, possibly by 
monocytes or a clonal population of T-
lymphocytes. These findings, in particular, 
suggest that thrombocytopenia in SLE may 
overlap with AMT. Alternatively, AMT may 
simply be an extreme manifestation of immune-
mediated thrombocytopenia in SLE. A wide 
range of therapies have been used in patients with 
AMT, including conventional 
immunosuppressive agents suc as steroid, anti-
thymocyte globulin, cyclosporine A, a 
thrombopoietin (TPO) nonpeptide mimetic 
(rituximab), immunomodulators such as 
intravenous immunoglobulin (IVIG), 
splenectomy, and allogeneic bone marrow 
transplant.  The evidence for each of these is 
weak, and based solely on anecdotal evidence. 
Supportive therapy involves platelet transfusions 
to reduce the risk of intra-cranial hemorrhage and 
other bleeding manifestations, so did in this 
patient.4,5,8 
The patient suffered from febrile neutropenia. 
Patients with a low ANC and prolonged 
neutropenia (eg, >10 days) are at further 
increased risk of infection. In this case, the patient 
suffered from severe febrile neutropenia  lasted 
more than 10 days. The history of recurrent 
furunculosis and oral apthae tend to be related to 
this condition, since lower the ANC, the greater 
possibility of getting an infection. With the 
improvement of the ANC, the furucle, oral apthae 
and the fever also diminished.  Based on the 
algorithm for the management of febrile 
neutropenia, the patient was administered single 
antibiotic injections (ceftazidim) for 5 days,  then 
administered double antibiotic injections with 
aminoglicoside gentamicyn. Although the fever 
had subsided, the ANC was still < 500 on the day 
7 of neutropenia, thus the administration of 
antibiotics was continued until the ANC  reached 
> 500/ µl. The ANC values had improved and 
reached >500/µl on 11th day admission, but 
because the neutropenia still persisted, the 
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antibiotic was conticoued with oral 
administration.10-13 
The etiology of SLE is unknown but genetic, 
environmental, and host immunologic factors are 
believed to interact and lead to disease 
expression. Autoantibody production is the 
hallmark of this disease with the mechanism 
leading  to loss of self-tolerance and some 
evidence suggests that immune complex-
mediated complement activation is important in 
the renal and vascular damage of SLE. The  
association between HLA  alleles and  the  level 
of various  autoantibodies has  also been  studied. 
Anti-Ro  and  anti-La  are powerfully associated 
with DR3/DR2  heterozygotes at  the DQ  alleles. 
Anti-Sm  and  anti-nRNP  tend  to  be associated 
with alleles on haplotypes containing a DR4 or a 
DQ3. Various  viruses  are  known  to be 
associated with SLE, including myxoviruses, 
reoviruses, measles, and rubella and ebstein-barr 
virus. The other environmental factors such as 
exposue to silica, mercury, pesticides, and drugs 
are also associated with SLE. In this case the 
etiology of the SLE was still unclear. There was 
no history of silica, mercury, pesticide and also 
drug exposure in this patients. The possibility of 
previous viral infection such as EB virus  
 















(b)Psychosis(having excluded other 
causes—for example, drugs) 
9.Haemolytic disorder 
(a)Haemolytic anaemia 
(b)Leucopenia or <4.0 x 10 9 /L on 
two or more occasions 
(c)Lymphopenia or <1.5 x 10 9 /L on 
two or more occasions 








(i)IgG/M anti cardiolipin 
antibodies 
(ii)Lupus anticoagulant 
(iii)False positive serological 
test for syphilis, present for at 
least 6months 
11.Antinuclear antibody in raised titre 
A person shall be said to have SLE if four 
or more of the 11 criteria are present, 
serially or simultaneously, during any 
interval of observation.’ 
 Revised criteria of the American College of Rheumatology for the 
classification   of SLE (modified from Hochberg, ArthritisRheum 
1997;40:1725–34) 
 
and the other virus as remaining possibility, but 
could not be prooved. The only environmental 
exposure she got was from sunlight. The genetic 
and immunologic susceptibility was perhaps were 
the main etiology of the SLE in this patient.1-3,9,14-
16 
The treatment for most manifestations of SLE 
does not differ among adults, children, and 
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adolescents. However, children and adolescents 
with SLE have unique problems related to growth 
and development that affect both the need for and 
the impact of aggressive therapy. If only skin and 
joints are affected, treatment with non steroidal 
anti-inflammatory drugs alone or in combination 
with hydroxyl chloroquine may be sufficient. 
Because most children who have SLE have at 
least one major organ system involved, they 
usually require treatment with corticosteroids. 
Low-dose prednisone (<0.5mg/kg/day) may be 
used for pleuritis as well as for persistent fever, 
skin involvement, and severe constitutional 
symptoms. Major organ disease (eg, diffuse 
proliferative glomerulonephritis) necessitates the 
use of high-dose prednisone. The initial dose is 
2mg/kg perday (maximum 60 to 80mg), a 
minimum of 3 to 4 weeks followed by 
consolidation and then a gradual decrease in 
dosage. Immunosuppressive medications are 
used for treating people with more severe 
manifestations of SLE, such as damage to internal 
organ. Other agents are used for SLE treatment 
are immunosuppressive medications include 
methotrexate, azathioprine, cyclophosphamide, 
chlorambucil, and cyclosporine. This patient was 
administered with methylprednisopolon 2 
mg/kg/day, due to bone marrow failure (AMT).1-
3,9,14,15,17,20 
The prognosis for children and 
adolescents with SLE who receive appropriate 
care is generally very good and presently, patients 
with SLE have a far better prognosis than 40 
years ago. The ten-year survival rate is now 
estimated to be 80%–90%. The survival rate for 
children and adolescents with SLE is nearly 
100% at 5 years and 85% at 10 years. The primary 
causes of an unsatisfactory outcome are due to 
poor compliance secondary to poor patient and 
family education, socioeconomic status of the 
family, increased disease activity, neurological 
complications, intercurrent infections, renal 
disease, and especially diffuse proliferative 
glomerulonephritis. Although the overall 
prognosis is said to be good, SLE is an episodic 
disease, with flare and remission. The more 
frequent a patients get flare episode, the 
prognosis is tend to be worse. In this patient, the 
AMT condition is a major factor that influence 
the prognosis, since the therapy agent for AMT is 
still underdebating and not available, the 
thrombocytopenia can be persistent, that 
increasing the possibility to spontaneous 
bleeding.1-3,9,18-,21   
SUMMARY 
 A case of Systemic Lupus Erythematosus 
(SLE) has been reported. SLE with 
Amegakaryocyte Trombocytopenia (AMT) in 
children is a rare case. Diagnosis of AMT was 
determined by bone marrow aspiration test which 
revealed isolated diminished megakaryocyte 
activity. The diagnosis of SLE was determined by 
ACR scorring system for SLE. The patient was 
administered antibiotics to overcome the febrile 
neutropenia, and steroid to prevent the SLE 
progressitivity. The clinical and laboratory 
parameter should be evaluated periodically in 
patient with SLE. Although literally the prognosis 
Jurnal Kesehatan Islam  e-ISSN : 2615-8345 
 
Page | 94  
 
of SLE in children is good, in this patient 
thrombocytopenia (AMT) is major factor that 
may worsen the prognosis. 
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